Ibogaine — Dissociative psychedelic / sigma-1 agonist / NMDA antagonist / opioid receptor modulator

The Stanford 2023 study by Nayak et al. (Nature Medicine) was landmark — veterans with TBI and PTSD showed dramatic improvements in PTSD scores, anxiety, and disability at 1-month follow-up after single ibogaine treatment. This is not purely addiction medicine; neurological benefits are being actively investigated. The cardiac risk is the primary barrier to widespread use — every ibogaine provider must have cardiac resuscitation capacity.

نظرة عامة

هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.

فئة المركّب

Dissociative psychedelic / sigma-1 agonist / NMDA antagonist / opioid receptor modulator

آلية العمل

Multi-target: NMDA antagonism (anti-addictive memory extinction), kappa-opioid receptor agonism (dysphoric purge), sigma-1 receptor agonism (neuroprotection), serotonin transporter inhibition, and noribogaine (active metabolite) binds opioid receptors for 48-72h providing extended anti-craving effect. FDA Breakthrough Therapy designation for opioid use disorder (2023). The noribogaine metabolite provides days-long afterglow that consolidates addiction interruption. Mechanism is distinct from all other addiction treatments.

الوضع التنظيمي

Schedule I USA; legal medical use in Mexico, Netherlands, some other countries; FDA Breakthrough designation allows IND trials

مستوى الأدلة

Moderate — Stanford 2023 (n=30) showed 80% success in opioid detox; FDA Breakthrough 2023; Phase 2 trials ongoing